Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)
China · Delayed Price · Currency is CNY 65.56
-4.47 (-6.38%)
At close: Mar 23, 2026
SHA:688336 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,199 | 1,179 | 1,005 | 817.88 | 928.12 |
Other Revenue | - | 14.89 | 9.2 | 7.61 | 0.69 |
| 4,199 | 1,194 | 1,014 | 825.49 | 928.81 | |
Revenue Growth (YoY) | 251.81% | 17.71% | 22.84% | -11.12% | 41.80% |
Cost of Revenue | - | 304.7 | 223.04 | 204.81 | 210.02 |
Gross Profit | 4,199 | 888.86 | 790.99 | 620.68 | 718.79 |
Selling, General & Admin | - | 316.73 | 314.89 | 333.18 | 367.15 |
Research & Development | - | 356.49 | 282.3 | 313.28 | 455.09 |
Other Operating Expenses | 905.8 | 9.3 | 9.37 | 6.23 | 4.11 |
Operating Expenses | 905.8 | 682.29 | 599.78 | 658.18 | 827.58 |
Operating Income | 3,293 | 206.58 | 191.21 | -37.5 | -108.79 |
Interest Expense | - | -1.18 | -1.4 | -1.32 | - |
Interest & Investment Income | - | 55.81 | 39.64 | 20 | 23.94 |
Earnings From Equity Investments | - | 395.8 | -16.4 | -15.48 | -3.28 |
Currency Exchange Gain (Loss) | - | -3.18 | 0.96 | 3.38 | -0.8 |
Other Non Operating Income (Expenses) | -8.11 | -0.27 | -0.17 | -0.11 | -0.18 |
EBT Excluding Unusual Items | 3,285 | 653.56 | 213.84 | -31.02 | -89.12 |
Gain (Loss) on Sale of Investments | - | 28.93 | 19.4 | 35.46 | 24.2 |
Gain (Loss) on Sale of Assets | - | 0.12 | 56.39 | -0.94 | -12.98 |
Other Unusual Items | - | 25.04 | 21 | 25.46 | 24.5 |
Pretax Income | 3,285 | 707.66 | 310.63 | 28.96 | -53.39 |
Income Tax Expense | 346.5 | 16.26 | 27.27 | -16.48 | -51.69 |
Earnings From Continuing Operations | 2,939 | 691.39 | 283.36 | 45.43 | -1.7 |
Minority Interest in Earnings | - | 13.19 | 11.25 | 3.86 | 19.75 |
Net Income | 2,939 | 704.58 | 294.61 | 49.3 | 18.06 |
Net Income to Common | 2,939 | 704.58 | 294.61 | 49.3 | 18.06 |
Net Income Growth | 317.09% | 139.15% | 497.63% | 172.99% | - |
Shares Outstanding (Basic) | 617 | 618 | 614 | 616 | 602 |
Shares Outstanding (Diluted) | 617 | 618 | 614 | 616 | 602 |
Shares Change (YoY) | -0.11% | 0.70% | -0.40% | 2.37% | 2.42% |
EPS (Basic) | 4.76 | 1.14 | 0.48 | 0.08 | 0.03 |
EPS (Diluted) | 4.76 | 1.14 | 0.48 | 0.08 | 0.03 |
EPS Growth | 317.54% | 137.50% | 500.00% | 166.67% | - |
Free Cash Flow | - | 0.35 | 180.61 | 12.23 | -507.61 |
Free Cash Flow Per Share | - | 0.00 | 0.29 | 0.02 | -0.84 |
Dividend Per Share | - | 0.123 | 0.050 | - | - |
Dividend Growth | - | 146.00% | - | - | - |
Gross Margin | 100.00% | 74.47% | 78.00% | 75.19% | 77.39% |
Operating Margin | 78.43% | 17.31% | 18.86% | -4.54% | -11.71% |
Profit Margin | 69.98% | 59.03% | 29.05% | 5.97% | 1.94% |
Free Cash Flow Margin | - | 0.03% | 17.81% | 1.48% | -54.65% |
EBITDA | 3,421 | 334.08 | 287.3 | 84.91 | 26.66 |
EBITDA Margin | 81.47% | 27.99% | 28.33% | 10.29% | 2.87% |
D&A For EBITDA | 127.51 | 127.51 | 96.08 | 122.41 | 135.46 |
EBIT | 3,293 | 206.58 | 191.21 | -37.5 | -108.79 |
EBIT Margin | 78.43% | 17.31% | 18.86% | -4.54% | -11.71% |
Effective Tax Rate | 10.55% | 2.30% | 8.78% | - | - |
Revenue as Reported | - | 1,194 | 1,014 | 825.49 | 928.81 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.